Event on
Transitioning to Endemic COVID-19 Testing: Evidence-Based Assessment on Current and Future Rapid Antigen Test Detection
CONTEXTE
Omicron globally became the predominant SARS-CoV-2 variant in late 2021. Some studies have suggested Omicron has a different replication pattern that could affect detection by rapid antigen tests. Reports in social media have promulgated oral swabs as a superior sample for detecting Omicron in the early stage of infection compared to nasal swabs.
More recently, publications report detection of Omicron by rapid antigen tests is comparable to the Delta Variant and other previous variants.
Objectifs Éducatifs
- Examine the latest clinical and scientific evidence related to rapid antigen test detection of COVID-19 in the presence of variants, including Omicron;
- Present recently published study results of rapid antigen test performance compared to PCR across sample types in a population infected with Omicron;
- Provide an outlook on future variants and potential impact on rapid tests;
- Assess clinical and public health guidance on rapid testing as the world transitions from pandemic to endemic patient care.
Présentations
-
Rajeeb Debray, MD
(UK)
Moderator -
Paul Drain, MD, MPH
(USA)
Speaker -
Amilcar Tanuri, MD, PhD
(Brazil)
SpeakerEvaluation of Subjects Infected with Omicron Variant Using RT-PCR and Antigen RDT (English)
-
Mary Rodgers, PhD
(USA)
Speaker -
Les points de vues et opinions présentés n’engagent que les orateurs. Le contenu de ce webcast est destiné à des fins informatives / éducatives uniquement.
© 2023 Abbott. Tous les droits sont réservés. Toutes les marques commerciales référencées sont des marques commerciales du groupe de sociétés Abbott ou de leurs propriétaires respectifs. COL-00000
